Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants

@article{Chirico2009CostutilityAO,
  title={Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants},
  author={Gaetano Chirico and Roberto Ravasio and Urbano Sbarigia},
  journal={Italian Journal of Pediatrics},
  year={2009},
  volume={35},
  pages={4 - 4}
}
INTRODUCTION The aim of this study was to assess the cost-utility of palivizumab versus no prophylaxis in the prevention of respiratory syncytial virus infection among high-risk preterm infants. METHODS We used and adapted a pre-existent model in which two cohorts of patients received palivizumab or no prophylaxis. The patients were followed for their expected lifetimes. The economic evaluation was conducted from the perspective of the Italian National Health Service. We considered Life-Years… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 25 references

Costo-efficacia di palivizumab versus non profilassi nella prevenzione delle infezioni da VRS nei bambini pretermine, a diversa età gestazionale

  • R Ravasio, C Lucioni, G Chirico
  • PharmacoEconomics – Italian Research Articles
  • 2006
Highly Influential
10 Excerpts

Progetto S.I.R.I.O (Social Impact of Respiratory Integrated Outcomes): Ricerca multicentrica nazionale sui costi generati dalle malattie respiratorie

  • RW Dal Negro, P Turco, WG Canonica
  • V Congresso Nazionale di Medicina Respiratoria,
  • 2004
1 Excerpt

Similar Papers

Loading similar papers…